Vancouver, British Columbia–(Newsfile Corp. – March 26, 2025) – BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (“BioMark”), a leading developer of liquid biopsy tests for early cancer detection, is pleased to announce that it has arranged and completed financing for the initial tranche of its non-brokered private placement (the “Private …
Read More »BioMark Diagnostics Underscores Commitment to Rare Disease Research on Rare Disease Day 2025
BioMark is pioneering liquid biopsy solutions for challenging conditions and championing equity in diagnosis Vancouver, British Columbia–(Newsfile Corp. – February 28, 2025) – BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) (“BioMark”), a leading developer of liquid biopsy tests for early cancer detection, proudly joins today the global …
Read More »